The 2026 J.P. Morgan Healthcare Conference revealed a shift in global pharmaceutical power dynamics, with China’s biotech sector commanding ever increasing attention from Western investors and executives who acknowledged the region’s transformation from manufacturing hub to innovation leader. You Cannot
‘We Created the Scene for Everyone Else’ Novo Nordisk CEO Maziar Mike Doustdar delivered a candid assessment of his company’s competitive position at the J.P. Morgan Healthcare Conference, characterizing the Danish drugmaker’s pioneering role in obesity treatment as both a
Richard Pazdur, MD, the longtime FDA drug regulator who abruptly left the agency in December, used his first public appearance at the J.P. Morgan Healthcare Conference this week to deliver a warning: the pharmaceutical industry is not taking concerns about
Guest Editorial by Audrey Greenberg, Venture Partner and Chair, Department of Business Development, Mayo Clinic Radiopharmaceuticals are accelerating clinically, but manufacturing infrastructure has not kept pace. Radioligand therapeutics exemplify the shift toward highly targeted therapeutics with outsized therapeutic impact, yet
Guest Editorial by Molly McGaughan, Co-founder and Managing Director, Firm Contract development and manufacturing organizations sit much closer to the patient experience than most people realize. Their decisions shape whether a dose arrives on time, whether rescheduling is possible, and
Guest Editorial by Clair Martin, Senior Engagement Manager, and Adam Siebert, Managing Director, LEK Consulting In radiopharmaceutical manufacturing, the real challenge is whether stated capacity can actually deliver reliable, end-to-end supply to patients under the tight timing constraints imposed by
Samsung Biologics has announced a three-pillar expansion strategy to establish itself as a global top-tier contract development and manufacturing organisation. Chief executive John Rim presented the company’s achievements and growth strategy at the 2026 J.P. Morgan Healthcare Conference in San
According to Bain & Company’s 2026 Global Healthcare Private Equity Report, 2025 was the largest year on record for pharma services deal value, yet transaction volumes declined 11% CAGR from their 2023 peak. Pharma Services Buyout Activity 2020-2025 Just three
“We’re not trying to be everything for everyone. Our specialized focus has been very exciting for me.” Franco Negron, CEO of Simtra BioPharma Solutions, has transformed a 65-year sterile manufacturing legacy into an independent CDMO since the company’s carve-out from
Johnson & Johnson announced Thursday it has reached an agreement with the Trump administration to reduce prescription drug prices for American patients in exchange for exemptions from pharmaceutical tariffs. The agreement makes J&J the 15th major pharmaceutical company to strike
